{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:42:22Z","timestamp":1777704142596,"version":"3.51.4"},"reference-count":28,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Toxicity-reduced conditioning is being used for allogeneic stem cell transplantation in older and\/or comorbid patients. We report on the treatment of 133 patients (median age: 55.6 years [23-73 years]) with acute myeloid leukemia (AML)\/myelodysplastic syndrome (MDS; n = 81), myeloproliferative syndromes (MPS; n = 20), and lymphoid malignancies (n = 32) using conditioning with FBM: fludarabine (5 \u00d7 30 mg\/m2), 1,3-bis(2-chloroethyl)-1-nitrosourea (or carmustine, BCNU; 2 \u00d7 200 mg\/m2), and melphalan (140 mg\/m2). Patients 55 years or older received fludarabine with reduced BCNU (2 \u00d7150 mg\/m2) and melphalan (110 mg\/m2). After engraftment, chimerism analyses revealed complete donor hematopoiesis in 95.7% of patients. With a median follow-up of 58.5 months, 3- and 5-year overall survival (OS) was 53.0% and 46.1%, event-free survival (EFS) was 46.4% and 41.9%. No significant differences in OS and EFS were evident considering disease status (early vs advanced), patient age (&lt;55 vs\u226555 years), or donor type (related vs unrelated) in univariate and multivariate analyses. The cumulative 5-year incidence of death due to relapse was 20.1%. Nonrelapse mortality (NRM) after 100 days and 1 year was 15.8% and 26.3%. Among patients with AML\/MDS, advanced cases (n = 64, including 61 with active disease) showed an OS of 44.6% and 42.4% after 3 and 5 years, respectively. Therefore, FBM conditioning combines effective disease control with low NRM.<\/jats:p>","DOI":"10.1182\/blood-2007-08-104745","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T05:35:12Z","timestamp":1209879312000},"page":"415-425","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies"],"prefix":"10.1182","volume":"112","author":[{"given":"Reinhard","family":"Marks","sequence":"first","affiliation":[{"name":"Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, Freiburg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, Freiburg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, University of Regensburg Medical Center, Regensburg; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Medical Informatics, Albert-Ludwigs University, Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, Freiburg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, Freiburg;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, University of Regensburg Medical Center, Regensburg; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Albert-Ludwigs University Medical Center, Freiburg;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111712380526200_B1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.","volume":"20","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"key":"2019111712380526200_B2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bmt.1705075","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: \u201cwhat is the best recipe?\u201d","volume":"36","author":"Kassim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019111712380526200_B3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"2019111712380526200_B4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"key":"2019111712380526200_B5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"key":"2019111712380526200_B6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","article-title":"Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.","volume":"21","author":"Bertz","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111712380526200_B7","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2003-03-0855","article-title":"Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.","volume":"102","author":"Wong","year":"2003","journal-title":"Blood"},{"key":"2019111712380526200_B8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"2019111712380526200_B9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111712380526200_B10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"2019111712380526200_B11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bmt.1702512","article-title":"Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.","volume":"26","author":"W\u00e4sch","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2019111712380526200_B12","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1182\/blood-2005-01-0196","article-title":"Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies.","volume":"105","author":"Spyridonidis","year":"2005","journal-title":"Blood"},{"key":"2019111712380526200_B13","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation.","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"key":"2019111712380526200_B14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2019111712380526200_B15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"2019111712380526200_B16","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"2019111712380526200_B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.leu.2403591","article-title":"Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.","volume":"19","author":"Shimoni","year":"2005","journal-title":"Leukemia"},{"key":"2019111712380526200_B18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"2019111712380526200_B19","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","article-title":"Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"2019111712380526200_B20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"2019111712380526200_B21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"2019111712380526200_B22","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1200\/JCO.2005.02.0057","article-title":"Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.","volume":"23","author":"Tauro","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111712380526200_B23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"2019111712380526200_B24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"2019111712380526200_B25","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"key":"2019111712380526200_B26","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","article-title":"Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"2019111712380526200_B27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2006.01.004","article-title":"Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.","volume":"43","author":"de Lima","year":"2006","journal-title":"Semin Hematol"},{"key":"2019111712380526200_B28","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","article-title":"Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.","volume":"23","author":"van Besien","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/2\/415\/1299811\/zh801408000415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/2\/415\/1299811\/zh801408000415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T17:38:17Z","timestamp":1574012297000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/2\/415\/24270\/Reducedtoxicity-conditioning-with-fludarabine-BCNU"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-08-104745","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}